Adaptive Biotechnologies Reports 36% Revenue Growth to $58.9 Million in Q2 2025

Adaptive Biotechnologies Corporation reported significant financial results for the second quarter of 2025, with total revenue reaching $58.9 million, a 36% increase from $43.2 million in the same period last year. For the first half of 2025, revenue totaled $111.3 million, up from $85.1 million in the first half of 2024. The company's net loss for the quarter was $25.6 million, a notable improvement compared to a net loss of $46.2 million in the prior year. For the six months ended June 30, 2025, the net loss was $55.5 million, down from $93.7 million in the same period of 2024.

The increase in revenue was primarily driven by a 42% rise in Minimal Residual Disease (MRD) revenue, which amounted to $49.9 million, compared to $35.3 million in the previous year. This growth was attributed to a $12.2 million increase in service revenue from the clonoSEQ test, as well as a $2.5 million rise in regulatory milestone revenue. The company reported a 37% increase in clonoSEQ test volume, delivering 25,321 tests in the second quarter of 2025, up from 18,520 tests in the same quarter of 2024. In contrast, Immune Medicine revenue grew modestly by 13% to $8.9 million, driven by collaboration revenue from the Genentech Agreement.

Operationally, Adaptive Biotechnologies has made strides in its strategic initiatives, including the expansion of its clonoSEQ test coverage under Medicare, which now includes single time point testing for monitoring recurrence in patients with a history of mantle cell lymphoma. The company has also integrated its clonoSEQ clinical diagnostic test into electronic medical record systems, enhancing accessibility for healthcare providers. As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $222 million, down from $256 million at the end of 2024.

Looking ahead, Adaptive Biotechnologies remains optimistic about its growth trajectory, particularly in the MRD segment, as it aims to increase clinical testing volume and expand into new patient populations. The company anticipates that its revenue will continue to grow as it advances its product offerings and enhances market penetration. However, it also acknowledges potential fluctuations in revenue due to the timing of customer sample receipts and regulatory milestones. The company plans to utilize its existing cash reserves to fund ongoing commercial activities, laboratory operations, and research and development initiatives.